CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Metronidazoledrug
Likely dose
Metronidazole 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00464542
NCT00464542Phase 4Completed
CompareCT.gov

Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding

University of Pittsburgh·interventional·Posted Apr 23, 2007·Updated May 11, 2017

In Brief

A Phase 4 clinical trial evaluating Metronidazole for Bacterial Vaginosis. Completed, enrolled 12 participants across 2 sites.

Detailed Summary

This investigation assessed the effects of asymptomatic BV on daily genital tract shedding of HSV-2 by determining shedding frequency before and after treatment of asymptomatic BV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 23, 2007
Enrollment StartDec 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.2 years ago

Interventions

Metronidazoledrug

500 mg, taken by mouth, two times a day, 7 days